Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The Company's pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
Type
Public
HQ
Hampton, US
Founded
1983
Size (employees)
205 (est)
Celldex Therapeutics was founded in 1983 and is headquartered in Hampton, US
Report incorrect company information

Key People/Management at Celldex Therapeutics

Anthony Marucci

Anthony Marucci

Founder, President & CEO
Tibor Keler

Tibor Keler

Founder, SVP & CSO
Thomas Davis

Thomas Davis

SVP & CMO
Ronald A. Pepin

Ronald A. Pepin

SVP & Chief Business Officer

Celldex Therapeutics Office Locations

Celldex Therapeutics has offices in Hampton, Branford, Fall River and Needham
Hampton, US (HQ)
220 53 I-78 Frontage Rd
Branford, US
1a 688 E Main St
Fall River, US
UMass Dartmouth Center for Innovation & Entrepreneurship 151 Martine St
Needham, US
119 4th Ave
Show all (4)
Report incorrect company information

Celldex Therapeutics Financials and Metrics

Celldex Therapeutics Financials

Celldex Therapeutics's revenue was reported to be $12.74 m in FY, 2017
USD

Revenue (FY, 2017)

12.7 m

Net income (FY, 2017)

(93 m)

EBIT (FY, 2017)

(121.5 m)

Market capitalization (23-Apr-2018)

88.8 m

Cash (31-Dec-2017)

40.3 m
Celldex Therapeutics's current market capitalization is $88.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

4.1 m3.6 m5.5 m12.7 m

Revenue growth, %

(13%)53%

General and administrative expense

25 m

R&D expense

96.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

980 k416 k592 k1.1 m2.2 m1 m1.3 m1.4 m2.2 m1.5 m3.8 m3.9 m

General and administrative expense

3.6 m4.6 m4.8 m5 m8.2 m8.5 m9.3 m7.8 m7 m7.2 m6.5 m

R&D expense

20.4 m27.1 m24.1 m26.2 m26.5 m24.7 m27.4 m25.7 m25 m25.8 m25 m

Operating expense total

24.2 m31.9 m29.1 m31.4 m34.9 m33.4 m37 m33.8 m32.2 m36.6 m32.8 m35.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

169.4 m28 m72.1 m42.5 m40.3 m

Accounts Receivable

489 k427 k97 k1.8 m

Current Assets

305.2 m205 m294.9 m195.6 m144.8 m

PP&E

10 m10.5 m11.5 m13.2 m10.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2017Q2, 2017Q3, 2017

Cash

14.6 m56.9 m40.8 m32.5 m42.5 m66.2 m54.7 m

Current Assets

139.9 m276.8 m255.6 m229.8 m173.5 m160.1 m147.3 m

PP&E

8.8 m10.2 m10.6 m10.7 m12.4 m12.1 m

Goodwill

9 m9 m9 m9 m91 m91 m91 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(81.6 m)(118.1 m)(127.2 m)(128.5 m)(93 m)

Depreciation and Amortization

1.9 m2.4 m3 m3.1 m4.4 m

Accounts Payable

7.2 m1.5 m4.9 m(5 m)(8.7 m)

Cash From Operating Activities

(67.7 m)(101.5 m)(98.9 m)(113 m)(99.9 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

(23.1 m)(29.9 m)(28.3 m)(28.1 m)(32.4 m)(32 m)(34.7 m)(32 m)(29.6 m)(34.3 m)(26.4 m)

Accounts Payable

1.2 m1.7 m3.1 m2 m1.2 m2.6 m706 k1 m2.7 m1.3 m
USDY, 2017

Revenue/Employee

63.1 k

Financial Leverage

1.3 x
Show all financial metrics

Celldex Therapeutics Operating Metrics

FY, 2016

Patents Issued

300
Show all operating metrics
Report incorrect company information